Cytiva has announced a new research partnership with the San Raffaele Telethon Institute for Gene Therapy (SRTIGET) to advance next-generation genomic medicine platforms.
The pair will focus on lentiviral gene transfer and targeted gene editing of haematopoietic stem cells.
This partnership also includes collaboration with two other Danaher companies: Aldevron and Integrated DNA Technologies (IDT).
Established under Danaher Beacons—long-term strategic research collaborations between Danaher companies and world-class academic institutions—the initiative aims to help researchers and developers address some of the most persistent bottlenecks in cell and gene therapy, targeting high-impact areas where even small gains can meaningfully accelerate the transition from discovery to delivery.
This new partnership is the first Danaher Beacon in the European Union.
SR-TIGET is a joint venture between Ospedale San Raffaele and Fondazione Telethon, an Italian non-profit organisation committed to advancing research for rare genetic diseases. Fondazione Telethon recently became the first non-profit to bring a gene therapy to market in the US.
It seeks to enhance access to innovative tools for translational researchers aiming to implement promising genomic technologies more quickly and reliably.
The new collaboration will unite SR-TIGET's scientific expertise with Cytiva's manufacturing capabilities, covering all stages from process development to commercialisation.
Why this matters
As more cell and gene therapies move into clinical pipelines—2025 saw 2130 clinical trials in progress—developers face increasing pressure to optimise processes, improve consistency, reduce costs and accelerate timelines.
The Cytiva-SR-TIGET initiative will prioritise high-impact areas where even modest advances can meaningfully accelerate translation and improve manufacturability.
The project will span several years as part of Cytiva's larger initiative to enhance its genomic medicine portfolio and support innovators throughout the biotech ecosystem.
Speaking exclusively to Manufacturing Chemist, Daria Donati, Chief Scientific Officer for Genomic Medicine at Cytiva, said: “Advancing genomic medicines requires collaboration between industry and academic institutions and the wider ecosystem."
This is a small extract of the full article which is available
ONLY to premium content subscribers.
Click below to get premium content on Manufacturing Chemist.
Not yet a Subscriber?